ROBERT SCHNACKENBERG: Open Payments
NPI 1548240484 · COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,452 in 88 payments from 14 companies in 2025. Trend: 2023 $957 · 2024 $1,546 · 2025 $1,452
Food & beverage: $1,452
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $321 |
| ABBVIE INC. | 33 | $277 |
| Bausch Health US, LLC | 9 | $197 |
| Neurocrine BioSciences, Inc. | 5 | $143 |
| Otsuka America Pharmaceutical, Inc. | 7 | $125 |
| Alkermes, Inc. | 5 | $105 |
| Lundbeck LLC | 4 | $79 |
| Noven Therapeutics, LLC | 4 | $64 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 1 | $26 |
Products named: CAPLYTA, VRAYLAR, REXULTI, APLENZIN, INGREZZA, LYBALVI, Xelstrym, ARISTADA.
Industry payments across SC — which companies pay providers there.
